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Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic encephalopathic state associated with reversible cerebral vasogenic edema that was first described in 1996. 1 The clinical presentation ranges from headaches to confusion or frank encephalopathy. Additionally, patients commonly have visual disturbances and seizures. 2 Brain imaging usually demonstrates abnormalities, preferentially in the bilateral parietooccipital lobes, which might be related to lower concentrations of sympathetic innervation of the posterior intracranial arteries in comparison with other cerebral regions. 3, 4 There is still controversy about the pathophysiological trigger; however, the mechanism that produces vasogenic edema seems to be associated with loss of integrity of the blood-brain barrier. Recognized risk factors that are commonly found at the onset of PRES include hypertension, preeclampsia/eclampsia, autoimmune disease, renal disease, infections, and multiple drugs (Table 1) . Moderate-to-severe hypertension is seen in 75% of patients with PRES. 5 However, the potential causes of PRES in the oncology population are diverse because these patients often receive multiple chemotherapy regimens, monoclonal antibody therapies, immunosuppressants, and stem cell transplantation. 6 -8 However, in contradistinction to other cancer patients, PRES is very uncommon in patients with primary brain tumors (PBTs). Only 3 adult and 5 pediatric cases have been reported in the literature 9 -14 , which indicates the challenge of diagnosing PRES. The diagnosis of PRES is particularly challenging in the PBT patient population because PERS can mimic the clinical and radiological features of brain tumor progression as well as central nervous system infections. The aim of this study was to analyze the clinical manifestations and radiological features and to report the clinical outcomes of PRES in PBT patients.
Anderson Cancer Center institutional database from 2012 -2014 under a protocol with waiver of consent having been approved by the institutional review board. All patients had undergone tumor biopsy or surgical resection with confirmed pathological diagnosis of a PBT and developed PRES during the course of disease. In addition, we also solicited cases from the literature. The diagnosis of PRES in all cases was confirmed by brain MRI using standard MRI sequences including axial T2 and FLAIR sequences, T1 axial pre-and postcontrast, T1 postcontrast in the coronal and sagittal planes, T2-gradient-echo axial, diffusionweighted imaging, and apparent diffusion coefficient (ADC) map. Pre-and postcontrast MRIs were performed on machines with either 1.5 tesla or 3 tesla units using a 22 mm field of view and 5 mm slice thickness with 1.5 mm gap. The radiological patterns were classified into typical and atypical according to the lesion distribution after Bartynski and Boardman. 8 The typical pattern includes involvement of the occipital, parietal, frontal, and temporal lobes as well as the cerebellum. Atypical cases include distinct involvement of basal ganglia, thalamus, corpus callosum, and the periventricular white matter in addition to partial expression of the typical pattern with lack of involvement in the parietal or occipital lobes. We collected demographic, treatment, and survival data from the database. Resolution of PRES was defined as radiological resolution of vasogenic edema. Death was confirmed by review of medical records, death certificate, and/or the Social Security Death Index. Additional clinical, neuropathological, and neuroimaging data were obtained from institutional electronic medical records. (Table reproduced with kind permission from, 7 Springer Science + Business Media: Curr Oncol Rep, Posterior reversible encephalopathy syndrome: a neurologic phenomenon in cancer patients, volume 5, 2014, 383, Le EM, Loghin ME, Table 2 ).
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Results
We searched our medical record database and identified 72 cases of PRES in cancer patients. Only 4 cases were PBT patients out of a total population of 1980. We also identified 3 more adult and 5 pediatric cases with a literature review. 9 -14 The median age at diagnosis of PRES was 19 years (range 4 -62y), and the male-to-female ratio was 1:1. PRES occurred in 4 patients with ependymoma, 3 patients with glioblastoma, 3 patients with diffuse intrinsic pontine glioma (DIPG), 1 patient with juvenile pilocytic astrocytoma, and 1 patient with atypical meningioma. Patient demographics and clinical characteristics are listed in Table 2 . Five patients received cancer treatment within 2 months of onset of PRES. The 4 cases from literature review had received antiangiogenic agents, either bevacizumab or vandetanib, and only one received intensive chemotherapy consisting of cisplatin, etoposide, vincristine, and temozolomide before the onset of symptoms. Four cases developed PRES in the perioperative period for posterior fossa tumors; 2 of those cases occurred intraoperatively. Clinical presentation included seizures (n ¼ 7), altered mental status (n ¼ 6), headache (n ¼ 3), focal neurological deficits (n ¼ 3; aphasia, dysphagia, vocal cord dysfunction), and visual changes (n ¼ 2). PRES was associated with elevated blood pressure in all patients. Three patients had a history of hypertension, but only one of them had good blood-pressure control. The median systolic, diastolic, and median arterial pressures at onset were 167 mmHg, 100 mmHg, and 122 mmHg, respectively. Two patients developed PRES within the context of acute kidney injury (case 2 with serum creatinine ¼ 3.9 mg/dL and case 4 with serum creatinine ¼ 1.9 md/dL). Mean platelet count and serum magnesium level were 152 K/uL and 2.2 mg/dL, respectively. Five patients had typical parietooccipital imaging findings, while 5 other patients had atypical imaging findings (Fig. 1) . One patient with a watershed distribution of PRES also developed infarctions in those areas with corresponding DWI restriction and ADC map changes that were confirmed by autopsy (Fig. 2) . Three of our MDACC patients recovered completely in 3 to 4 weeks after the onset of symptoms. One patient died due to active cancer and several comorbidities including PRES (case 2).
Discussion
PRES is being increasingly recognized in cancer patients. 15 -20 This recognition has led to an apparent increase in the incidence of PRES and earlier detection, although newer and more intensive treatments may also be contributing to the rise. PRES has been reported in patients who received platinum analogues (eg, cisplatin and carboplatin), 17,19 -21 antimetabolites (eg, gemcitabine), 17, 19, 22 folate antagonists, 23 -25 anthracyclines, 24 and the vinca alkaloids, 16 growth factors, 26, 27 immunosuppresants, 28, 29 monocloncal antibodies, 16, 18, 25, 30 or small molecule inhibitors 13, 15, 30, 31 (Table 1 ). The ready availability of sophisticated brain imaging has also contributed to early diagnosis.
The pathophysiology of PRES is still controversial, and there are 2 main hypotheses. One hypothesis involves impaired cerebral autoregulation responsible for an increase in cerebral blood flow (hyperperfusion), which may explain the changes that occur in hypertension. A second hypothesis involves endothelial dysfunction, which is thought to represent those cases with normal or minimally elevated blood pressure that do not fit within the paradigm of overwhelmed cerebral autoregulation. This eventually results in cerebral hypoperfusion and might be more relevant to cases of PRES associated with cytotoxic therapy and possibly uremia. The resultant pathway of both hypotheses is blood-brain barrier dysfunction and consequent cerebral vasogenic edema. 32 There are only 8 cases in the literature reporting an association between PBTs and PRES. Two cases had glioblastoma and received bevacizumab, 9,10 a monoclonal antibody that produces angiogenesis inhibition by blocking the vascular endothelial growth factor A (VEGF-A). Bevacizumab is known to cause hypertension as one of its most common adverse events, provoking cerebral vascular autoregulation breakthrough, but it can also cause endothelial dysfunction resultant in PRES. The association between bevacizumab and PRES has also been described in patients with cancer other than brain/spinal cord and includes gastrointestinal cancer, renal cell carcinoma, and breast cancer. 9 Two other cases had DIPG and received vandetanib, 13 an oral vascular endothelial growth factor receptor 2 and epidermal growth factor receptor inhibitor. Vandetanib also causes hypertension and may share the same pathophysiological pathway as bevacizumab in provoking PRES. Four cases had posterior fossa tumors consisting of ependymoma (3 cases) and juvenile pilocytic astrocytoma (1 case), with involvement of the fourth ventricle, medulla, brainstem, and cerebellum, respectively. Those 4 cases underwent excessive manipulation of the brainstem or cerebellum during surgery, leading to severe hypertension and development of PRES.
None of the MDACC cases received bevacizumab as a tumor treatment, nor did they develop thrombocytopenia or hypomagnesemia as is commonly reported in PRES, but 3 of them were exposed to chronic steroid use. The identified etiologies in these cases were sudden onset of hypertension and acute kidney injury, both of which are well-described causes of PRES. PRES distribution did not correlate with the brain tumor location, or specific tumor histology.
The recognition of PRES in patients with PBTs can be challenging because PRES can mimic various conditions such as tumor progression/recurrence, strokes, and infections that can lead to misdiagnosis and delay in treatment. Although the clinical presentation might be helpful in certain cases, diagnosis might still be difficult, especially in patients who present with focal neurological deficits and radiological findings atypical for PRES. A thorough workup in a timely manner, is necessary to assist with an early diagnosis in order to avoid complications. 33 Bartynski and Boardman have described typical or atypical radiological patterns of PRES in 136 patients, and atypical distribution of vasogenic edema was the most common pattern seen in their study. In contrast, the most common pattern in our cases was typical. One patient had a watershed distribution of T2 hyperintensity changes, which unfortunately progressed to ischemia with corresponding diffusion-weighted imaging restriction and ADC map changes ( Fig. 1C and D) . Although PRES is typically reversible, permanent neurological deficits due to ischemic infarction occur in about 10% -23% of cases, and this is why prompt correction of the underlying factors leading to PRES should be instituted as soon as possible. 8, 34 Three of our patients had clinical and radiological resolution of PRES after 3-4 weeks from onset, while the cases reported in the literature recovered after 8 -12 weeks from onset. 9, 11, 12, 14 The occurrence of PRS in children with cancer has also been increasing. Morris et al reported 11 pediatric cases with cancer Kamiya-Matsuoka et al.: PRES and primary brain tumors other than brain/spinal cord; the most frequent risk factors for developing PRES were intensive systemic chemotherapy and elevated blood pressure (apparently secondary to chronic steroid use or renal failure). All of the patients survived, but 6 of them had presented with recurrent seizures. 35 Case 2 in our study received intense chemotherapy and presented with elevated blood pressure as well as acute kidney injury. Unfortunately, the patient died after 1 week from active cancer and multiple comorbidities including PRES. Siebert et al reported radiological patterns of PRES in a series of 18 pediatric cases, most of them with autoimmune diseases and cancer but no PBTs. The holohemispheric watershed pattern was frequently seen (22%) and was associated with residual laminar necrosis in 23% of cases. 36 Interestingly, the same pattern was confirmed at autopsy in case 2. In the majority of children with cancer, PRES seems to leave radiological or clinical sequelae that may indicate a more aggressive clinical course than that seen in adults. 35 The current study describes a series of cases in which a diagnosis of PRES was made despite complicating issues associated with the concurrent existence of a primary brain tumor. These cases demonstrate that PRES remains a potential cause for neurological decline and is particularly relevant because it often reverses if recognized and treated appropriately. The relatively small number of patients, the retrospective nature of the data collection, and the patient accrual from a tertiary care center limit formal conclusions regarding the cause(s) of PRES from this series. Furthermore, the potential effects of chemotherapeutic agents predisposing PRES cannot be excluded nor accurately determined.
Despite these limitations, this study underscores the importance of having a high index of suspicion to enable early diagnosis and subsequent discontinuation of potential causes. Although no conclusions can be made, we suspect that the cause of PRES in these cases was either acute kidney injury or hypertension rather than the underlying tumor. This theory is further reinforced by the fact that the clinical and radiological course of PRES in brain tumor patients did not vary from the classical descriptions of PRES found in other causes. The presence of new, bilateral, and somewhat symmetrical edema, without correlation with the tumor/surgical cavity location, is the radiological hallmark and key for diagnosing PRES in the context of brain tumors and differentiating it from brain-tumor progression or worsening peritumoral edema. Resolution of PRES was an independent process even after evidence of tumor progression. Moreover, Lou et al suggested that bevacizumab may be reinitiated gradually using reduced dosing 9 after controlling risk factors such as hypertension and acute kidney injury, although we do not have information to either support or refute this claim. In cases associated with hypertension, we would suggest that the blood pressure be lowered gradually because a rapid reduction in blood pressure can cause or increase the size of the involved ischemic area. . Diffuse neuropil vacuolation (edema), more pronounced in the cortex (H&E stain, x40; scale bar, 500 mm) (B) accompanied by various degrees of acute neuronal damage (H&E stain, x400; scale bar, 50 mm; inset) (B). These changes are accentuated in the frontal, parietal, and occipital lobes bilaterally, where multiple small foci of reactive vascular proliferation and microhemorrhages are identified (H&E stain, x40; scale bar, 500 mm) (C). An inflammatory component is inconspicuous (H&E stain, x100; scale bar. 200 mm) (D); 2 hypereosinophilic, pyknotic neurons (arrows) in comparison with an unaffected neuron situated above (H&E stain, x400; scale bar, 50 mm; inset) (D).
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